Marksans Pharma Future Growth
Future criteria checks 4/6
Marksans Pharma is forecast to grow earnings and revenue by 20.6% and 19.1% per annum respectively while EPS is expected to grow by 20.3% per annum.
Key information
20.6%
Earnings growth rate
20.3%
EPS growth rate
Pharmaceuticals earnings growth | 18.8% |
Revenue growth rate | 19.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 26 Dec 2023 |
Recent future growth updates
No updates
Recent updates
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2025 | 26,332 | 4,066 | N/A | N/A | 1 |
3/31/2024 | 21,583 | 3,335 | N/A | N/A | 1 |
12/31/2023 | 21,034 | 3,164 | N/A | N/A | N/A |
9/30/2023 | 19,971 | 2,965 | 894 | 2,528 | N/A |
6/30/2023 | 19,184 | 2,743 | N/A | N/A | N/A |
3/31/2023 | 18,521 | 2,653 | 1,838 | 2,374 | N/A |
12/31/2022 | 17,842 | 2,123 | N/A | N/A | N/A |
9/30/2022 | 16,670 | 2,004 | 972 | 1,286 | N/A |
6/30/2022 | 15,756 | 1,847 | N/A | N/A | N/A |
3/31/2022 | 14,908 | 1,868 | 529 | 993 | N/A |
12/31/2021 | 14,069 | 2,367 | N/A | N/A | N/A |
9/30/2021 | 14,026 | 2,473 | 883 | 1,336 | N/A |
6/30/2021 | 14,064 | 2,518 | N/A | N/A | N/A |
3/31/2021 | 13,762 | 2,385 | 1,322 | 1,786 | N/A |
12/31/2020 | 13,817 | 2,018 | N/A | N/A | N/A |
9/30/2020 | 13,142 | 1,724 | 1,839 | 2,478 | N/A |
6/30/2020 | 12,203 | 1,476 | N/A | N/A | N/A |
3/31/2020 | 11,344 | 1,208 | 1,734 | 2,333 | N/A |
12/31/2019 | 10,463 | 879 | N/A | N/A | N/A |
9/30/2019 | 9,972 | 834 | 66 | 416 | N/A |
6/30/2019 | 10,099 | 780 | N/A | N/A | N/A |
3/31/2019 | 10,001 | 804 | 142 | 274 | N/A |
12/31/2018 | 9,523 | 666 | N/A | N/A | N/A |
9/30/2018 | 9,223 | 582 | N/A | N/A | N/A |
6/30/2018 | 9,272 | 463 | N/A | N/A | N/A |
3/31/2018 | 9,127 | 358 | 112 | 501 | N/A |
12/31/2017 | 8,918 | 343 | N/A | N/A | N/A |
9/30/2017 | 8,949 | 275 | N/A | N/A | N/A |
6/30/2017 | 8,015 | 187 | N/A | N/A | N/A |
3/31/2017 | 7,672 | 113 | N/A | 141 | N/A |
12/31/2016 | 7,926 | 70 | N/A | N/A | N/A |
9/30/2016 | 7,948 | 136 | N/A | N/A | N/A |
6/30/2016 | 8,699 | 481 | N/A | N/A | N/A |
3/31/2016 | 8,933 | 785 | N/A | 308 | N/A |
12/31/2015 | 8,536 | 1,093 | N/A | N/A | N/A |
9/30/2015 | 8,495 | 1,191 | N/A | N/A | N/A |
6/30/2015 | 8,045 | 1,154 | N/A | N/A | N/A |
3/31/2015 | 7,967 | 1,094 | N/A | 1,545 | N/A |
12/31/2014 | 7,850 | 950 | N/A | N/A | N/A |
9/30/2014 | 7,405 | 897 | N/A | N/A | N/A |
6/30/2014 | 6,914 | 786 | N/A | N/A | N/A |
3/31/2014 | 6,300 | 719 | N/A | 648 | N/A |
12/31/2013 | 5,950 | 1,020 | N/A | N/A | N/A |
9/30/2013 | 5,406 | 877 | N/A | N/A | N/A |
6/30/2013 | 4,848 | 817 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MARKSANS's forecast earnings growth (20.6% per year) is above the savings rate (6.7%).
Earnings vs Market: MARKSANS's earnings (20.6% per year) are forecast to grow faster than the Indian market (17.5% per year).
High Growth Earnings: MARKSANS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MARKSANS's revenue (19.1% per year) is forecast to grow faster than the Indian market (9.9% per year).
High Growth Revenue: MARKSANS's revenue (19.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MARKSANS's Return on Equity is forecast to be high in 3 years time